Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

CalciMedica Inc CALC

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.


NDAQ:CALC - Post by User

User Avatar Image
(11)
•••
  • alphaflightX
Post by alphaflighton May 05, 2022 8:58am
591 Views
Post# 34658049

Graycliff Intercepts 2M Gold Grading 20.52 g/t @Shakespeare

Graycliff Intercepts 2M Gold Grading 20.52 g/t @Shakespeare
 
Graycliff Exploration Intercepts 2 Metres of Gold Grading 20.52 g/t at Shakespeare Project, Ontario
 
TORONTO, ON – May 5, 2022 - Graycliff Exploration Limited (the “Company” or “Graycliff”) (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) is pleased to announce assay results from drilling on its Shakespeare Gold Project located on the prolific Canadian Shield near Sudbury, Ontario. The results are assays from Phase Three of the drilling program (see press release dated June 3, 2021) that focused on expanding the extent of gold mineralization proximal to the historic Miller Shaft where gold mining took place more than 100 years ago.
 
Drill Hole J-31 intersected 20.52 g/t gold (“Au”) over 2.00 metres (“m”) including 39.00 g/t Au over 1.00 m. Other notable intersections included 3.9 g/t Au over 2.00 m and 5.6 g/t over 1.00 m. Significant intervals for holes J-25-21 to J-33-21 are detailed below:
 
President and CEO James Macintosh stated: “The first twelve holes of Phase Three drilling continue to show good mineralization at depth. Holes 25 through 33 showed numerous anomalous intersections with higher gold grades below surface, at depth of greater than 140 metres. We continue to believe in the tremendous potential Shakespeare has to offer, especially as we drill deeper.”
 
Figure 1 - Holes J-25-21 to J-33-21 Locations and Cross Section
 
Qualified Person
 
Bruce Durham, P.Geo., is a Qualified Person, as that term is defined by Canadian regulatory guidelines under NI 43-101, and has read and approved the technical information contained in this press release.
 
About Graycliff Exploration Limited
Graycliff Exploration is a mineral exploration company focused on its 1,025 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of one crown patented lease, two crown leases and 40 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. Graycliff’s Baldwin Project is adjacent to the east and is comprised of 68 claims covering 1,500 hectares. This brings our total land package in the area to 2,525 hectares.
 
 
For more information, please contact investor relations at [email protected] or call 647-249-9298 ext. 322.
 
On Behalf of the Board of Directors,
 
James Macintosh
President and CEO
 
 

<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities